查找使用阿拉丁产品的科研文献

ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion

Shouyan Deng,Yibo Zhang,Huanbin Wang,Wenhua Liang,Lu Xie,Ning Li,Yuan Fang,Yiting Wang,Jiayang Liu,Hao Chi,Yufan Sun,Rui Ye,Lishen Shan,Jiawei Shi,Zan Shen,Yonggang Wang,Shuhang Wang,Jean-Philippe Brosseau,Feng Wang,Grace Liu,Yingfei Quan,Jie Xu

Cancer immunotherapy has transformed treatment possibilities, but its effectiveness differs significantly among patients, indicating the presence of alternative pathways for immune evasion. Here, we show that ITPRIPL1 functions as an inhibitory ligand of CD3ε, and its expression inhibits T cells in the tumor microenvironment. The binding of ITPRIPL1 extracellular domain to CD3ε on T cells significantly decreased calcium influx and ZAP70 phosphorylation, impeding initial T cell activation. Treatment with a neutralizing antibody against ITPRIPL1 restrained tumor growth and promoted T cell infiltration in mouse models across various solid tumor types. The antibody targeting canine ITPRIPL1 exhibited notable therapeutic efficacy against naturally occurring tumors in pet clinics. These findings highlight the role of ITPRIPL1 (or CD3L1, CD3ε ligand 1) in impeding T cell activation during the critical “signal one” phase. This discovery positions ITPRIPL1 as a promising therapeutic target against multiple tumor types.